Ghassan Aldurra, MD
Psychiatry · Hinsdale, ILNPI 1699781310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,287 of the $53,232 with a category attached, or 73.8%. Alkermes, Inc. accounts for 60.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $19,674 and has fallen 91.0% since, to $1,764 in 2025. Among psychiatry clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $106.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$32K
- Sunovion Pharmaceuticals Inc.$6K
- AbbVie$5K
- Tris Pharma Inc$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$1K
- plus $5K from 18 others
What the payments were for
- Speaking & faculty fees$39,28774%
- Travel & lodging$2,8735%
- Food & beverage$10,91821%
- Education$1540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 65 | $31,991 |
| Sunovion Pharmaceuticals Inc. | 38 | $5,928 |
| AbbVie(2 entities) | 54 | $4,942 |
| Tris Pharma Inc | 13 | $3,008 |
| Otsuka America Pharmaceutical, Inc. | 62 | $1,390 |
| Lundbeck LLC | 63 | $1,231 |
| Johnson & Johnson | 47 | $1,087 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $1,018 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $597 |
| Neurocrine Biosciences, Inc. | 13 | $382 |
| Bausch Health US, LLC | 18 | $347 |
| Teva Pharmaceuticals USA, Inc. | 11 | $346 |
| Axsome Therapeutics, Inc. | 11 | $275 |
| E.r. Squibb & Sons, L.L.C. | 4 | $126 |
| Shire North American Group Inc | 6 | $114 |
| Merck | 6 | $108 |
| Corium, LLC | 3 | $79 |
| Bristol Myers Squibb | 1 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $47 |
| USWM, LLC | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Almatica Pharma LLC | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Indivior Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$123,958
- LATUDA$5,448
- VRAYLAR$4,107
- Dyanavel XR$2,825
- Quillichew ER$2,825
- Quillivant$2,825
- REXULTI$238
How this compares
$53,232 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 37 | $106,563 |
| VraylarCariprazine Hcl | 24 | $33,589 |
| Abilify MaintenaAripiprazole | 11 | $22,984 |
| RexultiBrexpiprazole | 14 | $21,470 |
| Lurasidone Hcl | 49 | $6,781 |
| Aripiprazole | 241 | $5,706 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 73 | $1,833 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 37 | $1,830 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 137 | $1,705 |
| Escitalopram Oxalate | 140 | $1,700 |
| Quetiapine Fumarate | 148 | $1,692 |
| Olanzapine | 93 | $1,414 |
| Vilazodone Hcl | 17 | $1,260 |
| Clonazepam | 216 | $1,208 |
| Gabapentin | 81 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,087 | $106,56337 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,390 | $44,45425 claims |
| AbbVieVraylar | $4,942 | $33,58924 claims |
| Almatica Pharma LLCSertraline Hcl | $23 | $57648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Hinsdale
- Michael FeldNorthbrook$1.1M
- Jose MontesRockford$882K
- Mitchell GlaserChicago$752K
- Roukan JazayerliOrland Park$597K
- Ming XuBourbonnais$505K
- Peter WeidenChicago$440K
- Michelle DeesChicago$289K
- Mark ShukhmanSkokie$250K
- Abid NazeerOak Brook$228K
- Nitin ThaparOrland Park$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.